Data as of 1:24pm ET
| -0.04 / -2.29%|
The 3 analysts offering 12-month price forecasts for BioLine RX Ltd have a median target of 7.00, with a high estimate of 8.00 and a low estimate of 7.00. The median estimate represents a +309.36% increase from the last price of 1.71.
The current consensus among 3 polled investment analysts is to Buy stock in BioLine RX Ltd. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.